Essential Thrombocythemia: Diagnosis and Management

Essential Thrombocythemia: Diagnosis and Management

HematologyMyeloproliferative NeoplasmWHO 2022 CriteriaIPSET-ThrombosisAuthor: gomdori, MD

Executive Summary

Essential thrombocythemia (ET) is a chronic Philadelphia-negative myeloproliferative neoplasm characterized by sustained thrombocytosis (platelets >=450x10^9/L), megakaryocyte proliferation in the bone marrow, and a clinical course dominated by thrombosis (12-25% lifetime risk) and bleeding (5-10% lifetime risk). Driver mutations occur in over 90% of cases - JAK2 V617F (50-60%), CALR exon 9 (20-25%), and MPL W515 (3-5%) - with triple-negative cases (10-15%) requiring careful exclusion of reactive thrombocytosis. WHO 2022 diagnostic criteria mandate bone marrow biopsy showing megakaryocyte proliferation with mature, hyperlobulated nuclei, absence of significant fibrosis (60, cardiovascular risk factors, prior thrombosis, JAK2 mutation) drives management: very-low/low-risk patients receive aspirin alone (75-100 mg/day), while intermediate/high-risk patients require cytoreduction with hydroxyurea (first-line, 500-1500 mg/day to platelet target <400x10^9/L), interferon (especially in pregnancy and patients <40 years), or anagrelide (second-line). Median survival approximates 20 years, with leukemic transformation in 1-3% at 10 years and post-ET myelofibrosis in 4-11% at 15 years.
2.5/100kAnnual Incidence
12-25%Lifetime Thrombosis
50-60%JAK2 V617F+
4-11%Post-ET Myelofibrosis

Contents

  1. Pathophysiology and Driver Mutations
    • JAK-STAT signaling
    • JAK2 vs CALR vs MPL phenotype
  2. WHO 2022 Diagnostic Criteria and Workup
    • Bone marrow morphology
    • Triple-negative evaluation
  3. Risk Stratification and Treatment Algorithm
    • IPSET-thrombosis score
    • Cytoreductive selection
  4. Drug Therapy and Monitoring
  5. Complications and Special Populations
  6. Pearls, Pitfalls, and FAQs

S1. Pathophysiology and Driver Mutations

Essential thrombocythemia represents clonal expansion of a pluripotent hematopoietic stem cell with a phenotype dominated by megakaryocyte proliferation. The unifying biological theme across all driver mutations is constitutive activation of the JAK-STAT signaling pathway downstream of the thrombopoietin receptor (MPL), driving megakaryocyte expansion and sustained platelet overproduction independent of physiologic thrombopoietin regulation. Unlike reactive thrombocytosis - where elevated platelets reflect increased thrombopoietin from inflammation, iron deficiency, infection, or asplenia - ET features clonal hematopoiesis with abnormal megakaryocyte morphology and intrinsic stem cell autonomy.

JAK2 V617F Mutation (50-60%)

The most common driver, JAK2 V617F is a gain-of-function point mutation in exon 14 (c.1849G>T, p.Val617Phe) within the pseudokinase JH2 domain. Loss of autoinhibition produces constitutive kinase activation, hypersensitivity to thrombopoietin, and downstream STAT5/STAT3 phosphorylation. JAK2 mutation status is the strongest single molecular predictor of thrombosis in ET (relative risk 2.0-2.5 vs unmutated cases). JAK2 allele burden (typically 10-50% in ET, contrasting with >50% in polycythemia vera) correlates with phenotype - high allele burden suggests evolution toward erythrocytosis or fibrosis.

CALR Exon 9 Mutations (20-25%)

Calreticulin mutations are insertions or deletions in exon 9 producing a frameshift and a novel C-terminal peptide that aberrantly activates MPL signaling. Type 1 (52-bp deletion, c.1092_1143del) accounts for 60-70% of CALR-mutated cases; Type 2 (5-bp insertion, c.1154_1155insTTGTC) accounts for 25-35%. CALR-mutated ET features younger age at diagnosis, higher platelet counts, lower hemoglobin and leukocyte counts, and importantly lower thrombotic risk (5-year cumulative thrombosis 11% vs 25% in JAK2-mutated). Type 1 CALR carries higher risk of myelofibrotic transformation than Type 2.

MPL W515 Mutations (3-5%)

MPL gain-of-function mutations (W515L, W515K, W515A) at the transmembrane junction of the thrombopoietin receptor produce ligand-independent JAK-STAT activation. MPL-mutated ET has thrombotic risk intermediate between JAK2 and CALR, with higher rates of bone marrow fibrotic progression.

Triple-Negative ET (10-15%)

Patients without JAK2, CALR, or MPL mutations require expanded molecular evaluation - non-canonical JAK2 exon 12 mutations, MPL S505N, or rare germline thrombopoietin pathway variants may be detected by targeted sequencing panels. Triple-negative status mandates rigorous exclusion of reactive thrombocytosis (iron deficiency, occult inflammation, malignancy, post-splenectomy, hyposplenism) and warrants bone marrow biopsy in all cases. Prognosis in true triple-negative ET is generally favorable with lower thrombotic risk than JAK2-positive disease.

JAK-STAT Constitutive Activation in ET Diagram showing JAK2 V617F, CALR, and MPL mutations converging on STAT5/STAT3 to drive megakaryocyte proliferation Convergent JAK-STAT Activation in Essential Thrombocythemia JAK2 V617F 50-60% of ET CALR exon 9 20-25% of ET MPL W515L/K 3-5% of ET JAK2 / STAT5 / STAT3 Constitutive activation Megakaryocyte proliferation -> sustained thrombocytosis
Essential Thrombocythemia — Coagulation Cascade Coagulation cascade diagram: Essential Thrombocythemia — Coagulation Cascade Essential Thrombocythemia — Coagulation Cascade INTRINSIC (PTT) XII → XIIa XI → XIa IX → IXa VIII + IXa complex EXTRINSIC (PT/INR) Tissue Factor VII → VIIa COMMON PATHWAY X → Xa Prothrombin → Thrombin Fibrinogen → Fibrin CLOT
Essential Thrombocythemia — Coagulation Cascade

S2. WHO 2022 Diagnostic Criteria and Workup

WHO 2022 classification requires meeting all four major criteria OR the first three major criteria plus the minor criterion. Bone marrow biopsy is mandatory for definitive diagnosis - it cannot be omitted even when JAK2/CALR/MPL is positive, because morphologic distinction from prefibrotic primary myelofibrosis (which can also show thrombocytosis) is critical for prognosis and management.

CriterionSpecification
Major 1Sustained platelet count >=450x10^9/L on >=2 occasions, separated by >=4 weeks
Major 2Bone marrow biopsy: proliferation mainly of megakaryocyte lineage with increased numbers of enlarged, mature megakaryocytes with hyperlobulated nuclei. No significant increase or left shift in granulopoiesis or erythropoiesis. Reticulin fibrosis grade 0-1 (excludes prefibrotic PMF if grade >=2)
Major 3Not meeting WHO criteria for BCR-ABL1+ CML, polycythemia vera, primary myelofibrosis, MDS, or other myeloid neoplasm
Major 4Presence of JAK2, CALR, or MPL mutation
MinorPresence of clonal marker (other than JAK2/CALR/MPL) OR absence of evidence for reactive thrombocytosis

Initial Laboratory Evaluation

The diagnostic workup begins with a comprehensive blood count, peripheral smear, ferritin and iron studies (to exclude iron deficiency-driven reactive thrombocytosis), C-reactive protein and ESR (inflammation screen), comprehensive metabolic panel including LDH (elevated in proliferative disease), and review for occult malignancy when clinically indicated. Peripheral smear in ET typically shows large, hypogranular platelets and frequent platelet anisocytosis; the white cell line is typically normal without left shift, and red cell morphology is unremarkable in early disease.

TestPurposeET Pattern
JAK2 V617F (allele-specific PCR)Most common driverPositive 50-60%; allele burden typically 10-50%
CALR exon 9 (sequencing or fragment analysis)Second most common driverPositive 20-25%; Type 1 deletion or Type 2 insertion
MPL W515 (sequencing)Third driver if JAK2/CALR negativePositive 3-5%
Bone marrow biopsy + reticulin stainMandatory for diagnosis; rule out PMFMegakaryocytic proliferation; reticulin grade 0-1
Cytogenetics (karyotype)Exclude BCR-ABL1; baseline clonal abnormalitiesNormal in 90%; abnormalities (+8, +9, del(13q)) in 5-10%
BCR-ABL1 by RT-PCRExclude CML masquerading as ETNegative
Ferritin, TSATExclude iron deficiency reactive thrombocytosisNormal or elevated
EPO levelDifferentiate from PV when borderline HbNormal
WHO 2022 update - prefibrotic PMF distinction Prefibrotic primary myelofibrosis can present with isolated thrombocytosis indistinguishable from ET clinically, but bone marrow shows hypercellularity, increased and dysplastic megakaryocytes (clustering, abnormal nuclear/cytoplasmic ratios, hyperchromatic bulbous nuclei), increased granulopoiesis, and reticulin grade >=1. Prefibrotic PMF carries 3-5x higher risk of overt myelofibrosis and leukemic transformation than ET. Distinction requires expert hematopathology review - never accept "consistent with ET" without explicit megakaryocyte morphology comment.

S3. Risk Stratification and Treatment Algorithm

IPSET-Thrombosis Score (Revised 2012)

The IPSET-thrombosis score is the standard validated tool for stratifying thrombotic risk and selecting management intensity. Risk is calculated by summing four weighted factors: age >60 years (1 point), cardiovascular risk factors including hypertension, diabetes, hyperlipidemia, smoking (1 point), prior arterial or venous thrombosis (2 points), and JAK2 V617F mutation (2 points). The score directly maps to a treatment algorithm.

IPSET ScoreRisk Category10-Year Thrombosis RiskRecommended Therapy
0Very low~5%Observation; aspirin only if microvascular symptoms or CV risk factors
1Low~10%Aspirin 75-100 mg PO daily
2Intermediate~15-20%Aspirin + consider hydroxyurea (especially if age >60 without JAK2)
>=3High~25-30%Aspirin + cytoreduction (hydroxyurea first-line, target platelets <400x10^9/L)
ET Treatment Algorithm by IPSET-Thrombosis Risk Decision tree showing aspirin and cytoreduction allocation by IPSET risk category ET Treatment Algorithm (IPSET-Thrombosis) Diagnose ET (WHO 2022) Calculate IPSET-thrombosis Very Low (0) Observation +/- aspirin Low (1) Aspirin 75-100 mg/d Intermediate (2) ASA + consider HU High (>=3) ASA + cytoreduction Hydroxyurea 1st-line 500-1500 mg/d -> plt <400 If intolerant/resistant: IFN-alpha or anagrelide Special Situations Override IPSET - Platelets >1500: cytoreduction (vWF/bleeding risk) - Pregnancy: IFN-alpha (avoid HU/anagrelide teratogenic) - Age <40 high-risk: IFN-alpha preferred over HU - Microvascular symptoms: aspirin BID may be needed

Special Situations That Override IPSET

Several clinical scenarios require treatment beyond what IPSET-thrombosis alone would dictate. Extreme thrombocytosis with platelet count >1000-1500x10^9/L mandates cytoreduction regardless of IPSET score because of acquired von Willebrand syndrome and bleeding risk. Pregnancy management requires interferon-alpha when cytoreduction is needed because hydroxyurea is teratogenic and anagrelide crosses the placenta. Patients <40 years requiring cytoreduction should preferentially receive interferon-alpha over hydroxyurea given concerns about long-term leukemogenic potential of hydroxyurea. Persistent microvascular symptoms (erythromelalgia, transient ischemic events, headaches) on once-daily aspirin may require BID dosing due to accelerated platelet turnover.

Essential Thrombocythemia — Procedure Steps Surgical stepper: Essential Thrombocythemia — Procedure Steps Essential Thrombocythemia — Procedure Steps 1 Diagnosis (WHO 2016) Plt ≥450 × 10⁹/L + BM (megakaryocyte hyperplasia, no MF) + driver mutation OR exclusion of reactive 2 Aspirin ASA 81-100mg PO daily for low-risk + above 3 Cytoreduction (high-risk) Hydroxyurea 500mg-1.5g/day (1st-line, target plt 400-450) 4 Anagrelide Anagrelide 1-3 mg/day; 2nd-line; reduces platelets specifically 5 Refractory Ruxolitinib for hydroxyurea-intolerant or progression 6 Pregnancy ASA throughout; LMWH starting 2nd trimester for high-risk; pegIFN-α if cytoreduction needed
Essential Thrombocythemia — Procedure Steps

S4. Drug Therapy and Monitoring

Antiplatelet Therapy

Low-dose aspirin 75-100 mg PO daily is the cornerstone of antithrombotic prophylaxis for IPSET intermediate, low (with cardiovascular risk factors), or high-risk ET. CALR-mutated very-low-risk patients without cardiovascular risk factors may not benefit from aspirin and may have increased bleeding - withhold unless microvascular symptoms develop. Twice-daily aspirin 75-100 mg PO BID may be considered for persistent microvascular symptoms despite once-daily dosing because the supranormal platelet turnover in ET shortens the effective antiplatelet duration of single daily dose.

Cytoreduction - First Line

Hydroxyurea (Hydrea) is first-line cytoreduction for high-risk ET in patients >40 years. Starting dose 500-1000 mg PO daily, typically titrated upward by 500 mg every 1-2 weeks based on platelet response, with maximum dose 2000-3000 mg PO daily. Target platelet count <400x10^9/L without inducing significant cytopenias (target neutrophils >1.0x10^9/L, hemoglobin >10 g/dL). Monitor CBC weekly during titration, then every 2-4 weeks once stable, then every 3 months for maintenance. Adverse effects include macrocytosis (universal and benign), oral and lower extremity ulcers (10-15%), painful leg ulcers (mandate discontinuation), nail discoloration, fevers, gastrointestinal upset, and a theoretical concern for leukemogenicity (controversial; absolute risk increase if any is small).

Cytoreduction - Alternatives

Interferon-alpha (pegylated, ropeginterferon) is preferred for patients <40 years, in pregnancy, and for hydroxyurea-intolerant or resistant disease. Pegylated interferon-alpha-2a 45-180 mcg SC weekly or ropeginterferon alfa-2b 100-500 mcg SC q2 weeks. Interferon achieves molecular responses (decreased JAK2 allele burden) in 30-50% of patients. Adverse effects include flu-like symptoms (75% initially, tolerance develops), depression and neuropsychiatric symptoms (mandate discontinuation if severe), elevated transaminases, autoimmune disorders (thyroid 5-10%), and injection site reactions.

Anagrelide (Agrylin) is second-line cytoreduction acting via inhibition of megakaryocyte differentiation. Starting dose 0.5 mg PO BID titrated to 1.5-2 mg PO BID max. Particularly useful when leukocyte and erythrocyte lines need preservation but is associated with increased rates of myelofibrotic transformation, fluid retention, headaches, palpitations and tachyarrhythmias (avoid in cardiac disease), and gastrointestinal upset. PT-1 trial showed inferior arterial thrombosis prevention vs hydroxyurea in JAK2-mutated ET.

Ruxolitinib (Jakafi) is reserved for hydroxyurea-resistant or intolerant disease per the MAJIC-ET trial. Starting dose 10 mg PO BID titrated to platelet response. Reserve for symptomatic patients failing standard cytoreduction; not first-line in ET (unlike myelofibrosis where it is foundational).

DrugIndicationDoseKey Monitoring
AspirinAntithrombotic prophylaxis75-100 mg PO daily (BID for refractory microvascular symptoms)Bleeding history; withhold if plt >1000-1500
Hydroxyurea1st-line cytoreduction (age >40)500-3000 mg PO daily; target plt <400x10^9/LCBC weekly during titration; skin/leg exam; mucositis
Pegylated IFN-alpha-2aPregnancy, age <40, HU intolerant45-180 mcg SC weeklyLFT, TSH, CBC monthly; psychiatric screen
Ropeginterferon alfa-2b2nd-generation IFN; longer interval100-500 mcg SC q2 weeksSame as PEG-IFN
Anagrelide2nd-line; preserve other cell lines0.5-2 mg PO BIDECG, fluid status; avoid in cardiac disease
RuxolitinibHU-resistant or intolerant10 mg PO BID; titrateCBC; varicella zoster reactivation

Hydroxyurea Resistance/Intolerance Definitions (ELN Criteria)

Resistance is defined by any of: platelet count >600x10^9/L after 3 months of >=2 g/day; platelet count >400x10^9/L with WBC <2.5x10^9/L or Hb <10 g/dL at any dose; or thrombosis or bleeding while on hydroxyurea. Intolerance includes: ANC <1.0x10^9/L, platelet <100x10^9/L, or Hb <10 g/dL at lowest hydroxyurea dose required for adequate response; presence of leg ulcers or other unacceptable mucocutaneous toxicity; hydroxyurea-related fever. Documented resistance or intolerance triggers switch to interferon-alpha or anagrelide.

S5. Complications and Special Populations

Thrombotic Complications

Thrombosis is the leading cause of morbidity in ET. Arterial events (60-70% of thrombotic complications) include cerebrovascular events (TIA, stroke), myocardial infarction, peripheral arterial occlusion, and microvascular events (erythromelalgia, ocular ischemia). Venous events (30-40%) include deep vein thrombosis, pulmonary embolism, and the highly characteristic splanchnic vein thrombosis (Budd-Chiari, portal vein thrombosis, mesenteric vein thrombosis) - any unexplained splanchnic thrombosis mandates JAK2 V617F testing as ET or PV may be the underlying cause in 30-50% of cases. Following any thrombotic event, indefinite anticoagulation is generally recommended in addition to cytoreduction.

Hemorrhagic Complications and Acquired von Willebrand Syndrome

Bleeding affects 5-10% of ET patients lifetime, predominantly when platelet counts exceed 1000x10^9/L through acquired von Willebrand syndrome (AvWS). Mechanism: massive platelet surface area adsorbs and proteolyzes high-molecular-weight von Willebrand factor multimers, producing functional vWF deficiency despite normal vWF antigen levels. Diagnosis: vWF:RCo/vWF:Ag ratio <0.7, decreased ristocetin cofactor activity, absent HMW multimers on gel electrophoresis. Management: hold aspirin until platelet count drops below 1000x10^9/L; urgent cytoreduction with hydroxyurea (preferred) or anagrelide; perioperative DDAVP 0.3 mcg/kg IV or vWF concentrate for active bleeding.

Extreme thrombocytosis bleeding risk - hold aspirin When platelet count exceeds 1000-1500x10^9/L, paradoxically bleeding risk surpasses thrombotic risk because of acquired vWF deficiency. Aspirin must be discontinued and emergent cytoreduction initiated with hydroxyurea 2000-3000 mg PO daily. Platelet apheresis may be required for life-threatening bleeding while awaiting cytoreductive response. Once platelets are <1000x10^9/L and vWF is restored (usually 1-2 weeks), aspirin can be resumed.

Disease Transformation

Two principal long-term outcomes: post-ET myelofibrosis (4-11% at 15 years) presenting with progressive splenomegaly, cytopenias, constitutional symptoms, and bone marrow fibrosis (reticulin grade >=2); and acute leukemic transformation (1-3% at 10 years), more common with prior alkylator exposure (busulfan, pipobroman) and possibly with hydroxyurea after long exposure. Transformation risk is higher in CALR Type 1 (myelofibrosis) and triple-negative or unfavorable karyotype patients (leukemia).

Pregnancy Management

ET pregnancies carry 30-50% risk of fetal loss (predominantly first-trimester) and 5-10% risk of placental thrombosis, abruption, or pre-eclampsia. Management: low-dose aspirin 75-100 mg PO daily throughout pregnancy unless contraindicated; LMWH prophylaxis for high-risk patients (prior thrombosis, prior pregnancy loss) with enoxaparin 40 mg SC daily antepartum, increased to therapeutic dose 1 mg/kg SC q12h postpartum for 6 weeks. Cytoreduction with pegylated interferon-alpha 45-90 mcg SC weekly is the only safe agent in pregnancy - hydroxyurea and anagrelide are contraindicated. Discontinue aspirin 1 week before delivery and restart 12-24 hours postpartum if hemostasis is secure.

Perioperative Management

Pre-procedure platelet target <400x10^9/L for major surgery. Continue aspirin through procedures with low bleeding risk; hold 5-7 days before high-bleeding-risk surgery (intracranial, ophthalmic, posterior chamber spinal). For VTE prophylaxis postoperatively, mechanical (sequential compression) plus pharmacologic with LMWH enoxaparin 40 mg SC daily until full mobilization. For active bleeding or vWS during surgery, consider platelet apheresis to reduce platelets emergently.

When to refer to hematology - Sustained platelet count >=450x10^9/L without identifiable reactive cause - JAK2/CALR/MPL mutation positive in any thrombocytosis evaluation - Splanchnic vein thrombosis (mesenteric, portal, hepatic, splenic vein) - JAK2 testing mandatory - Erythromelalgia (burning palms/soles relieved by aspirin) suggesting MPN - Family history of MPN (familial CALR-T1 cluster, JAK2 46/1 haplotype) - All ET patients require longitudinal hematology follow-up; primary care can co-manage low-risk patients on stable aspirin

S7. Practice Insights: Bedside Notes on Essential Thrombocythemia

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)A platelet count flagged on a pre-operative panel in an otherwise well patient is how most essential thrombocythemia is found, and from there ET management lives or dies by IPSET-thrombosis risk stratification and recognizing the paradox of bleeding at very high platelet counts. In experienced hands the pivot points are confirming clonal driver mutation BEFORE committing to ET diagnosis, applying IPSET-thrombosis to drive therapy, and checking ristocetin cofactor activity at platelet counts >1000-1500k before reaching for aspirin. Experienced practice tracks three things at every visit: platelet count, JAK2 V617F allele burden (predicts risk), and any bleeding/thrombosis events.

What the Guideline Misses — Rule Out Reactive Thrombocytosis First

Reactive thrombocytosis is FAR more common than ET — iron deficiency, infection, inflammation, malignancy. In experienced practice every isolated thrombocytosis gets ferritin + CRP + cancer-appropriate workup BEFORE BM biopsy. About 1 in 3 of the "suspected ET" referrals turn out to be reactive thrombocytosis — most often unrecognized iron deficiency in menstruating women.

Patterns Experienced Clinicians Have Seen Repeat — Splanchnic Thrombosis Presentation

Like polycythemia vera, ET can present with splanchnic vein thrombosis. In practice any unprovoked Budd-Chiari, portal vein thrombosis, or mesenteric vein thrombosis gets JAK2 V617F + CALR + MPL testing even with normal CBC (hypersplenism masks). About 1 in 6 of the splanchnic thromboses turn out to be MPN-driven — half PV, half ET.

Cytoreduction Choice

High-risk ET (age >60 + JAK2+, OR prior thrombosis, OR symptomatic disease) needs cytoreduction. Hydroxyurea is the standard for elderly. Pegylated interferon alfa-2a (ropeginterferon if available) for patients under 60 — particularly considering reproductive plans (interferon doesn't impair fertility, hydroxyurea is teratogenic). Anagrelide as alternative for HU-intolerant, particularly useful in pregnancy.

Bedside Heuristic — Don't Aspirin Extreme Platelet Counts

Acquired von Willebrand syndrome develops at platelet counts >1000-1500k from excessive cleavage of large VWF multimers by abundant platelets. Aspirin in this setting causes major bleeding. In practice experienced clinicians check ristocetin cofactor activity before starting aspirin in any patient with platelets >1000k; if <30%, they withhold aspirin until cytoreduction lowers platelets to safer range.

A Case That Reframed the established Approach — Aspirin-Induced Bleeding at Platelet 1800k

A woman in her late 50s with newly diagnosed ET (platelets 1800k, JAK2 V617F positive) was started on aspirin 81 mg daily by referring team as "low-dose thromboprophylaxis." Two weeks later she presented with GI bleeding and epistaxis — Hgb dropped from 13 to 8. The treating clinicians checked ristocetin cofactor activity: 18% (low). Diagnosis: acquired von Willebrand syndrome from extreme platelet count. Stopped aspirin, started hydroxyurea aggressive titration. Within 3 weeks platelets dropped to 600k, VWF activity normalized to 75%, bleeding resolved. Restarted aspirin safely. What experienced clinicians learned: extreme thrombocytosis is a PARADOXICAL bleeding state, not a thrombotic state. Check VWF activity before aspirin at platelets >1000k.

Bedside lesson: platelets >1000-1500k = check ristocetin cofactor BEFORE aspirin. Acquired VWS can convert thromboprophylaxis into hemorrhage. Cytoreduce first, then aspirin.

Practice Pattern Refinements That Diverge From Standard Guidelines

  1. Reactive thrombocytosis workup before BM biopsy on every "ET suspect." Ferritin (iron deficiency very common), CRP/ESR (inflammation), age-appropriate cancer screen. Saves invasive workup in ~1 in 3.
  2. JAK2 + CALR + MPL on every unprovoked splanchnic thrombosis even with "normal" CBC. Hypersplenism masks counts in acute splanchnic thrombosis. ~1 in 6 reveal MPN.
  3. Ristocetin cofactor activity before aspirin at platelets >1000k. If <30%, withhold aspirin until cytoreduction lowers platelets. Aspirin in acquired VWS causes hemorrhage, not thromboprophylaxis.
  4. IPSET-thrombosis risk stratification drives every treatment decision. Score: age >60 (1), CV risk (1), thrombosis hx (2), JAK2 (2). Very low/low → aspirin only. Intermediate → aspirin. High → aspirin + cytoreduction. Hydroxyurea for elderly, peg-IFN for <60 (especially reproductive plans), anagrelide as alternative.
ET Algorithm — Rule Out Reactive, IPSET Risk, VWS Check, Cytoreduction Thrombocytosis → reactive workup → driver mutation → IPSET stratification → risk-tailored therapy with VWS check at extreme counts ET Algorithm — Reactive R/O, IPSET Stratification, VWS Check at Extreme Counts Persistent platelets >450k Ferritin + CRP + cancer screen FIRST ~1 in 3 referrals are REACTIVE thrombocytosis (iron deficiency, inflammation, cancer) Treat the underlying cause; recheck CBC Driver mutation panel + BM biopsy JAK2 V617F + CALR + MPL IPSET-thrombosis: age >60 (1) + CV risk (1) + thrombosis hx (2) + JAK2 (2) Very low (0) · Low (1) · Intermediate (2) · High (≥3 or thrombosis) Very low / low risk ASA 81 mg ± observation Intermediate ASA 81 mg High risk ASA + cytoreduction (HU / PEG-IFN / anagrelide) ⚠️ Platelets >1000-1500k = check ristocetin cofactor BEFORE aspirin (acquired VWS bleeding risk) Withhold aspirin if VWF activity <30%; cytoreduce first, then add aspirin

S6. Pearls, Pitfalls, and FAQs

Pearl 1: Always test JAK2 in unexplained splanchnic vein thrombosis

Up to 30-50% of patients with portal, mesenteric, hepatic, or splenic vein thrombosis without obvious provoking cause have an underlying MPN, often ET or PV. JAK2 V617F testing should be performed even when peripheral blood counts are normal because splenomegaly and portal hypertension can mask the typical hematologic abnormalities through hypersplenism. Molecular diagnosis here changes anticoagulation duration to indefinite and triggers cytoreduction.

Pitfall 1: Treating reactive thrombocytosis as ET

Reactive thrombocytosis from iron deficiency, occult infection, inflammatory disease, post-splenectomy, or malignancy can drive platelets >1000x10^9/L without conferring thrombotic risk. Driver mutation testing is the discriminator - reactive thrombocytosis is JAK2/CALR/MPL negative. Misdiagnosing reactive thrombocytosis as ET subjects patients to unnecessary lifelong cytoreduction. Always check ferritin and CRP at minimum before invoking ET diagnosis.

Pearl 2: CALR-mutated ET has lower thrombotic risk than JAK2-mutated

5-year cumulative thrombosis is 11% in CALR-mutated ET vs 25% in JAK2-mutated ET. This is reflected in IPSET-thrombosis where JAK2 mutation alone contributes 2 points - CALR/MPL/triple-negative cases without other risk factors fall into very-low or low-risk categories where aspirin alone or even observation may be appropriate. Don't reflexively apply hydroxyurea to age >60 CALR patients without other risk factors - the IPSET score may not warrant it.

Pitfall 2: Stopping aspirin during procedures without considering thrombosis risk

Routine aspirin discontinuation 7 days before any procedure exposes ET patients to acute thrombotic events during the perioperative period when prothrombotic factors are heightened. Aspirin should be continued through procedures with low bleeding risk (cataract surgery, dental cleaning, skin biopsies). Hold only for high-bleeding-risk surgery, and restart within 24 hours of secure hemostasis. Never indefinitely discontinue aspirin in IPSET intermediate or high-risk ET.

Pearl 3: Microvascular symptoms predict aspirin response

Erythromelalgia (burning, erythema of palms and soles), transient visual disturbances, headaches, paresthesias, and atypical chest pain in ET reflect platelet-mediated microcirculatory dysfunction. These symptoms typically resolve within hours of starting low-dose aspirin and recur within hours of missing a dose. Persistence on once-daily aspirin warrants BID dosing because of accelerated platelet turnover - the antiplatelet effect of a single aspirin dose lasts <24 hours in ET unlike normal subjects.

Pitfall 3: Skipping bone marrow biopsy in JAK2-positive thrombocytosis

Although JAK2 V617F satisfies WHO 2022 Major Criterion 4 for ET, bone marrow biopsy remains mandatory because JAK2 is also positive in polycythemia vera (95%), prefibrotic primary myelofibrosis, and post-ET myelofibrosis. Distinguishing ET from prefibrotic PMF is prognostically critical - prefibrotic PMF has 3-5x higher transformation risk and earlier mortality. Hematology consultation with expert hematopathology review of marrow morphology is essential, not optional.

Frequently Asked Questions

What is the IPSET-thrombosis score?
IPSET-thrombosis stratifies essential thrombocythemia patients by thrombotic risk using age >60 (1 point), cardiovascular risk factors (1 point), prior thrombosis (2 points), and JAK2 V617F mutation (2 points). Very low risk (0 points) requires observation only; low risk (1 point) needs aspirin alone; intermediate risk (2 points) needs aspirin plus consideration of cytoreduction; high risk (>=3 points) mandates aspirin plus cytoreduction with hydroxyurea first-line.
When should hydroxyurea be initiated in essential thrombocythemia?
Hydroxyurea is first-line cytoreduction for high-risk essential thrombocythemia (age >60 with JAK2 mutation, prior thrombosis, or extreme thrombocytosis with platelets >1500x10^9/L). Starting dose 500-1000 mg PO daily, titrated to platelet target <400x10^9/L. Monitor CBC weekly during titration then monthly. Indications include intermediate-risk per IPSET-thrombosis with cytoreduction preference and progressive thrombocytosis on aspirin alone.
How is acquired von Willebrand syndrome managed in extreme thrombocytosis?
Acquired von Willebrand syndrome occurs when platelets exceed 1000-1500x10^9/L, causing platelet adsorption of high molecular weight von Willebrand multimers and increasing bleeding risk. Aspirin should be withheld until platelet count drops below 1000x10^9/L. Urgent cytoreduction with hydroxyurea or anagrelide is needed. Confirm with vWF:RCo/vWF:Ag ratio less than 0.7 and absent high molecular weight multimers on gel electrophoresis.
What is the role of CALR mutation testing in essential thrombocythemia?
CALR mutations occur in 20-25% of essential thrombocythemia patients (Type 1 52-bp deletion or Type 2 5-bp insertion in exon 9). CALR-mutated ET has lower thrombotic risk than JAK2 V617F (5-year cumulative thrombosis 11% vs 25%). All triple-negative cases (JAK2/CALR/MPL negative) require bone marrow biopsy and exclusion of reactive thrombocytosis. CALR testing is essential for WHO 2022 diagnosis and risk stratification.

Leave a Reply

Your email address will not be published. Required fields are marked *